Disease-specific astrocyte states (distinct from classical A1/A2 paradigm) show compartmentalized responses with APOE4 carriers displaying exacerbated reactivity signatures. Reactive astrocytes downregulate glutamate transporters (SLC1A2/EAAT2) and upregulate GFAP/C3 in subsets, but many show non-classical disease-associated states. APOE4->E2 conversion via astrocyte-targeted AAV represents the most tractable therapeutic approach, though the A1/A2 framework validity is contested.
Interactive 3D viewer powered by RCSB PDB / Mol*. Use mouse to rotate, scroll to zoom.
Dimension Scores
How to read this chart:
Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential.
The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength),
green shows moderate-weight factors (safety, competition), and
yellow shows supporting dimensions (data availability, reproducibility).
Percentage weights indicate relative importance in the composite score.
6 citations6 with PMIDValidation: 0%3 supporting / 3 opposing
✓For(3)
No supporting evidence
No opposing evidence
(3)Against✗
HighMediumLow
HighMediumLow
Evidence Matrix — sortable by strength/year, click Abstract to expand
Evidence Types
5
1
MECH 5CLIN 1GENE 0EPID 0
Claim
Stance
Category
Source
Strength ↕
Year ↕
Quality ↕
PMIDs
Abstract
APOE4 carriers show exacerbated astrocyte reactivi…
Multi-persona evaluation:
This hypothesis was debated by AI agents with complementary expertise.
The Theorist explores mechanisms,
the Skeptic challenges assumptions,
the Domain Expert assesses real-world feasibility, and
the Synthesizer produces final scores.
Expand each card to see their arguments.
Gap Analysis | 4 rounds | 2026-04-22 | View Analysis
🧬TheoristProposes novel mechanisms and generates creative hypotheses▼
Cell Type Vulnerability in Alzheimer's Disease: SEA-AD v4 Analysis
Title: Layer-specific excitatory neurons show greatest transcriptomic vulnerability in SEA-AD, with mitochondrial dysfunction and synaptic gene downregulation as primary mechanisms
Mechanism: Deep layer excitatory neurons (layer 5-6) and superficial layer 2/3 neurons display the most pronounced AD-related gene expression changes, characterized by:
Downregulation of synaptic transmis
🔍SkepticIdentifies weaknesses, alternative explanations, and methodological concerns▼
Critical Evaluation of Cell Type Vulnerability Hypotheses in SEA-AD v4
Methodological Preface
Before evaluating individual hypotheses, several global limitations of the SEA-AD dataset must be acknowledged:
Cross-sectional design: Post-mortem tissue cannot resolve temporal causality—observed transcriptional changes may be primary disease mechanisms or downstream consequences
Survival bias: Severely affected brains may be overrepresented; rapidly degenerated cell types may be depleted from tissue
Agonal state confounds: Hypoxia, acidosis, and medication effects i
🎯Domain ExpertAssesses practical feasibility, druggability, and clinical translation▼
Feasibility Assessment: SEA-AD v4 Cell Type Vulnerability Hypotheses
Executive Summary
Following the Skeptics' downgrade of all hypotheses (range: 0.51–0.65 confidence), I assessed the surviving mechanistic threads through a drug discovery lens. Only Hypotheses 1 (MAPT/tau), 3 (microglialTYROBP), and 5 (APOE) emerge as Phase I-ready within a 5–7 year horizon. Hypotheses 2 (oligodendrocyte) and 7 (complement) have conditional feasibility pending model validation. Hypotheses 4 (inhibitory) and 6 (vascular) face significant translational barriers.
Hypothesis 1: Excitatory Neur
⚖SynthesizerIntegrates perspectives and produces final ranked assessments▼
{ "ranked_hypotheses": [ { "title": "Excitatory Neuron Synaptic Dysfunction and Mitochondrial Stress via MAPT (tau)", "description": "Deep layer (L5/6) and superficial layer (L2/3) excitatory neurons demonstrate the most pronounced transcriptomic vulnerability in SEA-AD, characterized by synaptic gene downregulation (SNAP25, SYT1, SLC17A7), stress response upregulation (HSPA1B, DNAJB1), and mitochondrial dysfunction signatures. MAPT (tau) emerges as the primary upstream driver with established Phase I-ready ASO and antibody modalities. Layer-specific markers (RORB, THEMIS) pr